SPORE in Endometrial Cancer
子宫内膜癌中的孢子
基本信息
- 批准号:8119020
- 负责人:
- 金额:$ 47.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-18 至 2014-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This Specialized Program of Research Excellence (SPORE) in Endometrial Cancer is submitted by Washington University in St. Louis, the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. It includes four research projects, three supportive cores, and research and career development programs. This proposal brings together basic and applied investigators to conduct innovative and diverse translational investigations aimed at preventing, diagnosing and treating endometrial cancer. The four projects in our application have been carefully designed to have significant potential to change clinical practice within five years.
Project 1: FGFR2 as therapeutic target in endometrial cancer
Project 2: Methylation markers for prognosis in endometrioid endometrial cancers
Project 3: Identifying inherited endometrial cancer & the environmental and genetic factors contributing to somatic loss of mismatch repair
Project 4: Novel effectors of ERK signaling and their potential roles in the treatment of endometrial cancer
The four projects represent carefully chosen marriages between selected endometrial cancer research priorities and the strengths of Washington University and our collaborators. The critical objectives that we have chosen to focus on are to: 1) improve the treatment of patients with persistent or recurrent endometrial cancer using a molecularly targeted therapy and determine if upfront adjuvant biologic therapies hold promise for improving outcomes in the general endometrial cancer population; 2) develop prognostic markers to help guide the treatment of women with the most common form of uterine tumors, endometrioid endometrial cancer; 3) optimize detection of those women with inherited forms of endometrial cancer so they and their at-risk family members can receive risk-appropriate (intensified) cancer surveillance; and 4) elucidate the role novel effectors of ERK signaling play in uterine cancer and assess opportunities for targeting these in the treatment of endometrial cancers.
Three Cores will support these projects: Administration, Tissue & Pathology, and Biostatistics. The Developmental Research Program will support a pathway for continued identification and support of diverse research that could replace or improve current projects, and a Career Development Program will recruit and support candidates committed to training in translational research in endometrial cancer.
这个子宫内膜癌卓越研究(SPORE)的专业计划由圣路易斯的华盛顿大学、巴恩斯犹太医院的Siteman癌症中心和华盛顿大学医学院提交。它包括四个研究项目,三个支持核心,以及研究和职业发展计划。该提案汇集了基础和应用研究人员,以进行旨在预防,诊断和治疗子宫内膜癌的创新和多样化的转化研究。我们申请的四个项目经过精心设计,具有在五年内改变临床实践的巨大潜力。
项目一: FGFR 2作为子宫内膜癌治疗靶点
项目二: 子宫内膜样癌的甲基化标志物与预后
项目三: 识别遗传性子宫内膜癌&导致体细胞错配修复缺失的环境和遗传因素
项目四: ERK信号通路的新效应物及其在子宫内膜癌治疗中的作用
这四个项目代表了子宫内膜癌研究重点与华盛顿大学和我们合作者的优势之间精心选择的婚姻。我们选择关注的关键目标是:1)使用分子靶向治疗改善持续性或复发性子宫内膜癌患者的治疗,并确定前期辅助生物治疗是否有望改善一般子宫内膜癌人群的结局; 2)开发预后标志物,以帮助指导最常见的子宫肿瘤形式,子宫内膜样癌的妇女的治疗; 3)优化对遗传性子宫内膜癌妇女的检测,使她们及其高危家庭成员能够接受风险适当的(强化的)癌症监测; 4)阐明ERK信号传导的新型效应物在子宫癌中的作用,并评估在子宫内膜癌治疗中靶向这些效应物的机会。
三个核心将支持这些项目:管理,组织和病理学,生物统计学。发展研究计划将支持一条途径,继续识别和支持可以取代或改进当前项目的各种研究,职业发展计划将招募和支持致力于子宫内膜癌转化研究培训的候选人。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Lineage-specific biomarkers predict response to FGFR inhibition.
谱系特异性生物标志物预测对 FGFR 抑制的反应。
- DOI:10.1158/2159-8290.cd-12-0486
- 发表时间:2012
- 期刊:
- 影响因子:28.2
- 作者:Loch,DavidC;Pollock,PamelaM
- 通讯作者:Pollock,PamelaM
Using the Wash U Epigenome Browser to examine genome-wide sequencing data.
- DOI:10.1002/0471250953.bi1010s40
- 发表时间:2012-12
- 期刊:
- 影响因子:0
- 作者:Zhou, Xin;Wang, Ting
- 通讯作者:Wang, Ting
Targeting mutant fibroblast growth factor receptors in cancer.
- DOI:10.1016/j.molmed.2011.01.012
- 发表时间:2011-05
- 期刊:
- 影响因子:13.6
- 作者:Greulich H;Pollock PM
- 通讯作者:Pollock PM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David G Mutch其他文献
David G Mutch的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David G Mutch', 18)}}的其他基金
Project 2: Inhibiting AXL to Improve Treatment Response in Endometrial Cancer
项目2:抑制AXL以改善子宫内膜癌的治疗反应
- 批准号:
10711637 - 财政年份:2023
- 资助金额:
$ 47.5万 - 项目类别:
相似海外基金
A novel mechanism of menopause-induced endometrial cancer that develops through functional loss of the helicase family
更年期诱发子宫内膜癌的新机制是通过解旋酶家族功能丧失而发生的
- 批准号:
24K19688 - 财政年份:2024
- 资助金额:
$ 47.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Project 3: Primary Prevention and Uterine Preservation in Premenopausal Women with Obesity and Endometrial Hyperplasia/Cancer
项目3:绝经前妇女肥胖和子宫内膜增生/癌症的一级预防和子宫保留
- 批准号:
10711638 - 财政年份:2023
- 资助金额:
$ 47.5万 - 项目类别:
Mechanisms of tamoxifen-associated endometrial cancer risk
他莫昔芬相关子宫内膜癌风险的机制
- 批准号:
10650054 - 财政年份:2023
- 资助金额:
$ 47.5万 - 项目类别:
Project 1: Targeting HSPA Proteins in Advanced and Recurrent Endometrial Cancer Therapy
项目 1:针对晚期和复发性子宫内膜癌治疗中的 HSPA 蛋白
- 批准号:
10711636 - 财政年份:2023
- 资助金额:
$ 47.5万 - 项目类别:
Development of new endocrine therapy based on genomic classification for endometrial cancer
基于子宫内膜癌基因组分类开发新内分泌疗法
- 批准号:
23K15818 - 财政年份:2023
- 资助金额:
$ 47.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Probing intratumor heterogeneity and elucidating developmental mechanisms based on cancer-associated genetic mutations in ovarian endometrial carcinoma
探讨卵巢子宫内膜癌肿瘤内异质性并阐明基于癌症相关基因突变的发育机制
- 批准号:
23K08857 - 财政年份:2023
- 资助金额:
$ 47.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Detection of imaging features related to node metastasis in uterine endometrial cancer
子宫内膜癌淋巴结转移相关影像学特征的检测
- 批准号:
23K07209 - 财政年份:2023
- 资助金额:
$ 47.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Claims-based measures of care coordination and long-term health among older women with endometrial cancer
患有子宫内膜癌的老年妇女的基于索赔的护理协调和长期健康措施
- 批准号:
10579456 - 财政年份:2023
- 资助金额:
$ 47.5万 - 项目类别:
Elucidation of molecular mechanisms involved in the diversity and plasticity of endometrial cancer stem cells and development of novel multifaceted therapies
阐明子宫内膜癌干细胞多样性和可塑性的分子机制并开发新型多方面疗法
- 批准号:
23H03044 - 财政年份:2023
- 资助金额:
$ 47.5万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Endometrial Cancer Survival and Survivorship among Latinas in California: A Mixed Methods Study
加利福尼亚州子宫内膜癌生存率和拉丁裔生存率:一项混合方法研究
- 批准号:
10461655 - 财政年份:2023
- 资助金额:
$ 47.5万 - 项目类别: